NCT05733013View on ClinicalTrials.gov

A Study to Collect Information About the Use of Redifferentiating Medications as a Standard Treatment for Thyroid Cancer

RecruitingOBSERVATIONAL

Enrollment

100

Participants

Timeline

Start Date

February 7, 2023

Primary Completion Date

February 7, 2028

Study Completion Date

February 7, 2028

Conditions

Thyroid CancerThyroidRefractory Thyroid Cancer

Interventions

OTHER

Surveillance Visit

Follow-up visits will be carried out at intervals per usual clinical practice. Tolerance of medication and adverse events will be recorded in every visit.

Trial Locations (1)

10065

RECRUITING

Memorial Sloan Kettering Cancer Center, New York

All Listed Sponsors

lead

Memorial Sloan Kettering Cancer Center

OTHER